Texas Permanent School Fund trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 206,764 shares of the medical research company’s stock after selling 8,415 shares during the period. Texas Permanent School Fund’s holdings in Amgen were worth $35,611,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its stake in Amgen by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock valued at $1,403,676,000 after acquiring an additional 195,200 shares during the period. Schwab Charles Investment Management Inc. raised its stake in Amgen by 1.6% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 2,894,780 shares of the medical research company’s stock valued at $474,947,000 after acquiring an additional 45,403 shares during the period. UBS Asset Management Americas Inc. raised its stake in Amgen by 3.1% in the 1st quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock valued at $446,250,000 after acquiring an additional 81,362 shares during the period. Swiss National Bank raised its stake in Amgen by 26.5% in the 1st quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock valued at $432,490,000 after acquiring an additional 551,600 shares during the period. Finally, Ameriprise Financial Inc. raised its stake in Amgen by 0.7% in the 1st quarter. Ameriprise Financial Inc. now owns 1,479,687 shares of the medical research company’s stock valued at $242,555,000 after acquiring an additional 10,109 shares during the period. Institutional investors own 78.10% of the company’s stock.
Shares of Amgen Inc. (NASDAQ AMGN) opened at 184.15 on Thursday. The stock has a 50 day moving average price of $182.76 and a 200-day moving average price of $170.66. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $191.10. The stock has a market capitalization of $134.37 billion, a PE ratio of 16.77 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.84 EPS. On average, analysts forecast that Amgen Inc. will post $12.58 earnings per share for the current year.
AMGN has been the topic of a number of research reports. Cann restated a “buy” rating on shares of Amgen in a research note on Monday, August 28th. Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $203.00 price target on shares of Amgen in a research report on Thursday, September 7th. Deutsche Bank AG began coverage on Amgen in a research report on Friday, June 23rd. They set a “hold” rating and a $172.00 price target on the stock. Mizuho reiterated a “buy” rating and set a $198.00 price target (up from $183.00) on shares of Amgen in a research report on Thursday, September 28th. Finally, William Blair reiterated a “market perform” rating on shares of Amgen in a research report on Monday, June 26th. Ten research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $189.99.
In other news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Monday, October 9th. The stock was sold at an average price of $185.95, for a total value of $283,573.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.19% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.